Novel ADC Technology to Increase Pancreatic Cancer Therapeutics Market by Substantial Rate

Novel ADC Technology to Increase Pancreatic Cancer Therapeutics Market by Substantial Rate

Release Date: 03-Nov-2020



It has been verified that the size of the tumor has a very strong impact on the overall survival rate in the patients suffering from pancreatic cancer. As per research findings, it has been observed that the overall survival rate in the patients suffering from pancreatic cancer is only 10%. Also, another important parameter that is associated with pancreatic cancer is that is very difficult to get cured with surgery. In addition to this, pancreatic cancer is also associated with poor survival rate in case gets treated with immunotherapy or nanomedicine therapy. It is found that the outcomes that are observed in the case of pancreatic cancer are mainly due to the complex microenvironment of the cancer cells.

 

Therefore, the researchers working on this respective study were more inclined towards developing novel targeted therapeutics that can target the pancreatic cancer cells instead of having complex microenvironment. The researchers have developed a novel chemo-immunotherapy agent carrying the capability to penetrate into the pancreatic tumor cells and further kill the cancer cells. The antibody-drug conjugate develop by the researchers is estimated to provide desired outcomes in the patients.

 

Due to their capability of targeting only cancer cells and leaving healthy neighbouring tissues, researchers were keen to implement such methodology on the treatment of pancreatic cancer. The developed antibody-drug conjugate by the researchers consisted of antibody that was specific to the molecule present on the cancer cells i.e. ICAM1 and a drug that was toxic to the cancer cells. The potent drug developed by the researchers was ultra-small so that it could reach to the pancreatic cells and provide better results when compared with T cell immunotherapy or nanomedicines.

 

It was analyzed that the mice models which received DM1-ICM1 observed a reduction in the size of the tumor cells after two weeks of treatment. Also, the treatment was joined with MRI-based molecular imaging technique in order to confirm the presence of the antibody drug conjugate at the site of the tumor. This was estimated to check the effect and monitor the drug in the model organisms after certain intervals. It is analysed that their methodology could lead to both specific targeting as well as analysis of the approach.

Need custom market research solution? We can help you with that too.